advanced SOFT TISSUE SARCOMA

Soft tissue sarcoma (STS) is a malignant tumor of connective tissue, accounting for about **1% OF ALL HUMAN CANCERS.**

STS can develop from soft tissues like fat, muscle, nerves, fibrous tissues, blood vessels or deep skin tissues



MORE THAN HALF DEVELOP IN THE ARMS OR LEGS

SOME SIGNS AND SYMPTOMS OF aSTS MAY INCLUDE:

Increasing abdominal pain

A new lump or a lump that is growing (anywhere on the body)

Blood in the stool or vomit

Black, tarry stools

MOST COMMON PRIMARY SITES OF STS

EXTREMITIES
43%
THE LUNGS ARE THE MOST COMMON SITE OF METASTASIS IN PATIENTS WITH STS OF THE EXTREMITIES

INTERNAL ORGANS
19%



RETROPERITONEUM
15%
(CONTAINS THE KIDNEYS, PANCREAS AND PART OF THE HEART)

THE TRUNK
10%

HEAD AND NECK
9%

approximately **50% OF PATIENTS** are diagnosed with or expected to progress to advanced or metastatic disease (aSTS)

The 5-year SURVIVAL RATE for aSTS is 16%

Patients with aSTS have a poor prognosis, with a median overall survival (OS) of **8 TO 12 MONTHS** from time of advanced diagnosis

DIAGNOSIS



ULTRASOUND may be the first exam, but it should be followed by a **CT** or **MRI**





Following appropriate imaging assessment, the standard approach to diagnosis consists of multiple core needle biopsies



MANAGEMENT OF aSTS

A MULTIDISCIPLINARY APPROACH is recommended, which can include support from pathologists, radiologists, surgeons, radiation therapists, medical oncologists as well as nuclear medicine specialists and organ specialists.

SURGERY
- surgery is the most common first treatment for sarcomas that are small and in specific locations

RADIATION THERAPY
- chemotherapy and radiation treatment options may be combined

SYSTEMIC THERAPY
- conventional cytotoxic chemotherapy is the standard treatment option for aSTS patients

TARGETED THERAPIES
- these therapies aim to disrupt the cancer's cell growth and survival

NOVARTIS
Novartis Pharma AG
CH-4002 Basel Switzerland

January 2016

G-VOT-1131077